Rational combinations of immunotherapeutics that target discrete pathways

Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors

(2013) J. Duraiswamy et al.   CANCER RESEARCH

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

(2013) Tyler R. Simpson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

(2013) S. Spranger et al.   Science Translational Medicine

DNGR-1 is a specific and universal marker of mouse and human Batf3-dependent dendritic cells in lymphoid and nonlymphoid tissues

(2012) L. F. Poulin et al.   BLOOD

Higher numbers of T-bet+ intratumoral lymphoid cells correlate with better survival in gastric cancer

(2012) Lu-jun Chen et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas

(2012) Muhammad Baghdadi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

MAGE-A antigens as targets in tumour therapy

(2012) David W. Meek et al.   CANCER LETTERS

LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

(2012) W. Zou et al.   CANCER RESEARCH

Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma

(2012) S. Miyamoto et al.   CANCER RESEARCH

Molecular Pathways: Tumor-Infiltrating Myeloid Cells and Reactive Oxygen Species in Regulation of Tumor Microenvironment

(2012) T. Lu et al.   CLINICAL CANCER RESEARCH

Development of an Fc-Enhanced Anti-B7-H3 Monoclonal Antibody with Potent Antitumor Activity

(2012) D. Loo et al.   CLINICAL CANCER RESEARCH

Tim-3, a negative regulator of anti-tumor immunity

(2012) Ana Carrizosa Anderson   CURRENT OPINION IN IMMUNOLOGY

Metabolism of L-Arginine by Myeloid-Derived Suppressor Cells in Cancer: Mechanisms of T cell suppression and Therapeutic Perspectives

(2012) Patrick Raber et al.   IMMUNOLOGICAL INVESTIGATIONS

Immunotherapeutic applications of IL-15

(2012) Michela Croce et al.   Immunotherapy

The dendritic cell receptor DNGR-1 controls endocytic handling of necrotic cell antigens to favor cross-priming of CTLs in virus-infected mice

(2012) Santiago Zelenay et al.   JOURNAL OF CLINICAL INVESTIGATION

Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo

(2012) Yan Zheng et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Cellular and Molecular Requirements for Rejection of B16 Melanoma in the Setting of Regulatory T Cell Depletion and Homeostatic Proliferation

(2012) J. Kline et al.   JOURNAL OF IMMUNOLOGY

IFN-  in the Treatment of Melanoma

(2012) A. A. Tarhini et al.   JOURNAL OF IMMUNOLOGY

Immunotherapy of Cancer with 4-1BB

(2012) D. S. Vinay et al.   MOLECULAR CANCER THERAPEUTICS

Cancer immunotherapy

(2012) Thomas F. Gajewski   Molecular Oncology

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype

(2012) A. G. Chapuis et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

CD25 Blockade Depletes and Selectively Reprograms Regulatory T Cells in Concert with Immunotherapy in Cancer Patients

(2012) A. J. Rech et al.   Science Translational Medicine

Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma

(2011) Sucheta Telang et al.   BMC CANCER

An immune-active tumor microenvironment favors clinical response to ipilimumab

(2011) Rui-Ru Ji et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The Efficacy of Radiotherapy Relies upon Induction of Type I Interferon-Dependent Innate and Adaptive Immunity

(2011) B. C. Burnette et al.   CANCER RESEARCH

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

(2011) S.-R. Woo et al.   CANCER RESEARCH

Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives

(2011) J. Godin-Ethier et al.   CLINICAL CANCER RESEARCH

Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

(2011) S. A. Rosenberg et al.   CLINICAL CANCER RESEARCH

Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma

(2011) Ahmad A. Tarhini et al.   JOURNAL OF CLINICAL ONCOLOGY

Host type I IFN signals are required for antitumor CD8+T cell responses through CD8α+dendritic cells

(2011) Mercedes B. Fuertes et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Type I interferon is selectively required by dendritic cells for immune rejection of tumors

(2011) Mark S. Diamond et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma

(2011) S M Ansell et al.   LEUKEMIA

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

(2010) X. Liu et al.   BLOOD

Depletion of CD4+CD25high regulatory T cells from tumor infiltrating lymphocytes predominantly induces Th1 type immune response in vivo which inhibits tumor growth in adoptive immunotherapy

(2010) Lin Xu et al.   CANCER BIOLOGY & THERAPY

Gene Signature in Melanoma Associated With Clinical Activity

(2010) Thomas F. Gajewski et al.   CANCER JOURNAL

Anti-tumor immune response induced by dendritic cells transduced with truncated PSMA IRES 4-1BBL recombinant adenoviruses

(2010) Kuang Youlin et al.   CANCER LETTERS

Selective Depletion of Foxp3+ Regulatory T Cells Improves Effective Therapeutic Vaccination against Established Melanoma

(2010) K. Klages et al.   CANCER RESEARCH

Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor

(2010) Y. Zhao et al.   CANCER RESEARCH

Translating Tumor Antigens into Cancer Vaccines

(2010) Luigi Buonaguro et al.   Clinical and Vaccine Immunology

Induction of T cell anergy: integration of environmental cues and infectious tolerance

(2010) Pascal Chappert et al.   CURRENT OPINION IN IMMUNOLOGY

Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment

(2010) Thomas F Gajewski et al.   CURRENT OPINION IN IMMUNOLOGY

The CD4-like molecule LAG-3, biology and therapeutic applications

(2010) Sophie Sierro et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

MAGE A3 antigen-specific cancer immunotherapeutic

(2010) Nir Peled et al.   Immunotherapy

Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Bystander killing of cancer requires the cooperation of CD4+and CD8+T cells during the effector phase

(2010) Andrea Schietinger et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Characterization of human DNGR-1+BDCA3+leukocytes as putative equivalents of mouse CD8α+dendritic cells

(2010) Lionel Franz Poulin et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

(2010) Kaori Sakuishi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

A Pilot Study of Denileukin Diftitox (DD) in Combination With High-dose Interleukin-2 (IL-2) for Patients With Metastatic Renal Cell Carcinoma (RCC)

(2010) Elizabeth Atchison et al.   JOURNAL OF IMMUNOTHERAPY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Signaling Through OX40 Enhances Antitumor Immunity

(2010) Shawn M. Jensen et al.   SEMINARS IN ONCOLOGY

Immune Modulation with Interleukin-21

(2009) Neela S. Bhave et al.   Annals of the New York Academy of Sciences

Clinical Use of Anti-CD25 Antibody Daclizumab to Enhance Immune Responses to Tumor Antigen Vaccination by Targeting Regulatory T cells

(2009) Andrew J. Rech et al.   Annals of the New York Academy of Sciences

FOXP3 Defines Regulatory T Cells in Human Tumor and Autoimmune Disease

(2009) I. Kryczek et al.   CANCER RESEARCH

The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

(2009) M. A. Cheever et al.   CLINICAL CANCER RESEARCH

MAGRIT: The Largest-Ever Phase III Lung Cancer Trial Aims to Establish a Novel Tumor-Specific Approach to Therapy

(2009) Preeta Tyagi et al.   Clinical Lung Cancer

Costimulatory and coinhibitory receptors in anti-tumor immunity

(2009) Gregory Driessens et al.   IMMUNOLOGICAL REVIEWS

Promoting Immune Responses by LIGHT in the Face of Abundant Regulatory T Cell Inhibition

(2009) Y. Wang et al.   JOURNAL OF IMMUNOLOGY

Serum-Soluble B7x Is Elevated in Renal Cell Carcinoma Patients and Is Associated with Advanced Stage

(2008) R. H. Thompson et al.   CANCER RESEARCH

Homeostatic Proliferation Plus Regulatory T-Cell Depletion Promotes Potent Rejection of B16 Melanoma

(2008) J. Kline et al.   CLINICAL CANCER RESEARCH

Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

(2008) R. Berger et al.   CLINICAL CANCER RESEARCH

Molecular regulation of T-cell anergy

(2008) Yan Zheng et al.   EMBO REPORTS

Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens

(2008) Mark E. Dudley et al.   JOURNAL OF CLINICAL ONCOLOGY

Transient T cell depletion causes regression of melanoma metastases

(2008) Mary Rasku et al.   Journal of Translational Medicine

Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1

(2008) Naomi N. Hunder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Batf3 Deficiency Reveals a Critical Role for CD8 + Dendritic Cells in Cytotoxic T Cell Immunity

(2008) K. Hildner et al.   SCIENCE

Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy

(2007) Ronald J Buckanovich et al.   NATURE MEDICINE